Tratamiento del asma bronquial
Barra lateral del artículo
Contenido principal del artículo
Resumen
.
Downloads
Detalles del artículo
Sección
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Cómo citar
Referencias
Global Initiative for Asthma. Global strategyfor asthma management and prevention. Rev.2002. [Bethesda, Md.] : National Institutes ofHealth, National Heart, Lung, and Blood Institute,[2002]. (NIH publication; no. 02-3659).
James AL, Palmer LJ, Kicic E, et al. Declinein lung function in the Busselton Health Study:the effects of asthma and cigarette smoking. AmJ Respir Crit Care Med 2005;171(2):109-14 DOI: https://doi.org/10.1164/rccm.200402-230OC
O’Byrne PM, Pedersen S, Busse WW, et al.Effects of early intervention with inhaledbudesonide on lung function in newly diagnosedasthma. Chest 2006;129(6):1478-85. DOI: https://doi.org/10.1378/chest.129.6.1478
Vignola AM, Mirabella F, Costanzo G, et al.Airway remodeling in asthma. Chest 2003;123(3 Suppl):417S-22S. DOI: https://doi.org/10.1378/chest.123.3_suppl.417S
Bateman ED, Boushey HA, Bousquet J, etal. Can guideline-defined asthma control beachieved? The Gaining Optimal AsthmaControl study. Am J Respir Crit Care Med2004;170(8):836-44. DOI: https://doi.org/10.1164/rccm.200401-033OC
McKay LI, Cidlowski JA. Molecular controlof immune/inflammatory responses: interactionsbetween nuclear factor-kappa B and steroidreceptor-signaling pathways. Endocr Rev1999;20(4):435-59. DOI: https://doi.org/10.1210/edrv.20.4.0375
Childhood Asthma Management ProgramResearch Group. Long-term effects of budesonideor nedocromil in children with asthma. N EnglJ Med 2000;343(15):1054-63. DOI: https://doi.org/10.1056/NEJM200010123431501
Kelly HW. Comparative potency and clinicalefficacy of inhaled corticosteroids. Respir CareClin N Am 1999 Dec;5(4):537-53.
Lipworth BJ. Adrenal suppression withinhaled corticosteroids. Ann Allergy AsthmaImmunol 2001;87(5):359-61. DOI: https://doi.org/10.1016/S1081-1206(10)62914-6
Lange P, Scharling H, Ulrik CS, et al.Inhaled corticosteroids and decline of lungfunction in community residents with asthma.Thorax 2006;61(2):100-4. DOI: https://doi.org/10.1136/thx.2004.037978
Rodrigo GJ, Castro-Rodriguez JA.Anticholinergics in the treatment of children andadults with acute asthma: a systematic reviewwith meta-analysis. Thorax 2005;60(9):740-6.Errata en: Thorax 2006;61(3):274 y Thorax2006;61(5):458 DOI: https://doi.org/10.1136/thx.2005.047803
Barnes PJ. Theophylline: new perspectivesfor an old drug. Am J Respir Crit Care Med2003 Mar 15;167(6):813-8. DOI: https://doi.org/10.1164/rccm.200210-1142PP
Calhoun WJ, Lavins BJ, Minkwitz MC, etal. Effect of zafirlukast (Accolate) on cellularmediators of inflammation: bronchoalveolarlavage fluid findings after segmental antigenchallenge. Am J Respir Crit Care Med 1998May;157(5 Pt 1):1381-9. DOI: https://doi.org/10.1164/ajrccm.157.5.9609014
Suissa S, Dennis R, Ernst P, et al. Effectivenessof the leukotriene receptor antagonist zafirlukastfor mild-to-moderate asthma. A randomized,double-blind, placebo-controlled trial. AnnIntern Med 1997;126(3):177-83. DOI: https://doi.org/10.7326/0003-4819-126-3-199702010-00001
Malmstrom K, Rodriguez-Gomez G,Guerra J, et al. Oral montelukast, inhaledbeclomethasone, and placebo for chronicasthma. A randomized, controlled trial.Montelukast/Beclomethasone Study Group.Ann Intern Med 1999;130(6):487-95. DOI: https://doi.org/10.7326/0003-4819-130-6-199903160-00005
Powell H, Gibson PG. High dose versuslow dose inhaled corticosteroid as initial startingdose for asthma in adults and children.Cochrane Database Syst Rev 2004;(2):CD004109. DOI: https://doi.org/10.1002/14651858.CD004109.pub2
Lipworth BJ. Systemic adverse effects ofinhaled corticosteroid therapy: A systematicreview and meta-analysis. Arch Intern Med1999;159(9):941-55 DOI: https://doi.org/10.1001/archinte.159.9.941
Barnes PJ. Scientific rationale for inhaledcombination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J2002;19(1):182-91. DOI: https://doi.org/10.1183/09031936.02.00283202
Greening AP. Ind PW, Northfield M, et al.Added salmeterol versus higher-dosecorticosteroid in asthma patients with symptomson existing inhaled corticosteroid. Allen &Hanburys Limited UK Study Group. Lancet1994 Jul; 344(8917):219-224. DOI: https://doi.org/10.1016/S0140-6736(94)92996-3
Calhoun WJ, Lavins BJ, Minkwitz MC, etal. Effect of zafirlukast (Accolate) on cellularmediators of inflammation: bronchoalveolarlavage fluid findings after segmental antigenchallenge. Am J Respir Crit Care Med 1998May;157(5 Pt 1):1381-9. DOI: https://doi.org/10.1164/ajrccm.157.5.9609014
Suissa S, Dennis R, Ernst P, et al. Effectivenessof the leukotriene receptor antagonist zafirlukastfor mild-to-moderate asthma. A randomized,double-blind, placebo-controlled trial. AnnIntern Med 1997;126(3):177-83. DOI: https://doi.org/10.7326/0003-4819-126-3-199702010-00001
Malmstrom K, Rodriguez-Gomez G,Guerra J, et al. Oral montelukast, inhaledbeclomethasone, and placebo for chronicasthma. A randomized, controlled trial.Montelukast/Beclomethasone Study Group.Ann Intern Med 1999;130(6):487- DOI: https://doi.org/10.7326/0003-4819-130-6-199903160-00005
Ducharme FM, Lasserson TJ, Cates CJ.Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaledcorticosteroids for chronic asthma. CochraneDatabase Syst Rev 2006;(4):CD003137 DOI: https://doi.org/10.1002/14651858.CD003137.pub3
Evans DJ, Taylor DA, Zetterstrom O, et al.A comparison of low-dose inhaled budesonideplus theophylline and high-dose inhaledbudesonide for moderate asthma. N Engl J Med1997;337(20):1412-8. DOI: https://doi.org/10.1056/NEJM199711133372002
Prussin C, Griffith DT, Boesel KM, et al.Omalizumab treatment downregulates dendriticcell FcepsilonRI expression. J Allergy ClinImmunol 2003;112(6):1147-54. DOI: https://doi.org/10.1016/j.jaci.2003.10.003
Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children.Cochrane Database Syst Rev 2006;(2):CD003559 DOI: https://doi.org/10.1002/14651858.CD003559.pub3